© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Septerna Inc (SEPN) stock surged +1.61%, trading at $37.97 on NASDAQ, up from the previous close of $37.37. The stock opened at $37.28, fluctuating between $36.71 and $39.37 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 09, 2026 | 37.15 | 39.40 | 37.15 | 37.97 | 475.29K |
| Sep 08, 2026 | 36.15 | 38.06 | 36.01 | 37.37 | 309.7K |
| Sep 04, 2026 | 36.57 | 37.59 | 36.57 | 36.75 | 199.66K |
| Sep 03, 2026 | 37.72 | 38.20 | 36.46 | 36.80 | 241.54K |
| Sep 02, 2026 | 37.96 | 38.86 | 37.24 | 37.50 | 263.22K |
| Sep 01, 2026 | 38.15 | 38.57 | 37.24 | 37.68 | 263.95K |
| Aug 31, 2026 | 38.71 | 39.10 | 37.39 | 38.15 | 415.3K |
| Aug 28, 2026 | 40.25 | 40.95 | 38.74 | 38.91 | 385.85K |
| Aug 27, 2026 | 40.01 | 41.08 | 39.95 | 40.47 | 266.54K |
| Aug 26, 2026 | 41.08 | 41.36 | 40.12 | 40.25 | 168.18K |
| Aug 25, 2026 | 41.57 | 41.85 | 40.47 | 41.30 | 333.22K |
| Aug 24, 2026 | 39.76 | 40.90 | 38.96 | 40.52 | 520.47K |
| Aug 21, 2026 | 41.44 | 41.44 | 39.95 | 40.00 | 289.81K |
| Aug 20, 2026 | 43.15 | 43.62 | 40.24 | 40.79 | 429.95K |
| Aug 19, 2026 | 44.65 | 44.93 | 43.49 | 43.93 | 383.52K |
| Aug 18, 2026 | 43.69 | 44.58 | 43.37 | 43.80 | 332.51K |
| Aug 17, 2026 | 44.01 | 45.41 | 43.69 | 44.20 | 433.67K |
| Aug 14, 2026 | 45.00 | 46.50 | 43.64 | 44.50 | 630.34K |
| Aug 13, 2026 | 47.83 | 48.95 | 45.10 | 45.14 | 877.64K |
| Aug 12, 2026 | 47.93 | 51.10 | 47.40 | 48.19 | 1.26M |
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves’ disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women’s health, cardiovascular disease, and respiratory disease. It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.
| Employees | 123 |
| Beta | 2.29 |
| Sales or Revenue | N/A |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | N/A |
| Sector | Healthcare |
| Industry | Biotechnology |